Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
American Well Corporation (Amwell) is a digital health company operating in the telehealth and healthcare technology industries. The company provides a cloud-based platform that enables healthcare providers, health systems, and health plans to deliver virtual care services, including urgent care, primary care, specialty consultations, and behavioral health. Amwell’s core value proposition centers on enterprise-grade telehealth infrastructure designed to integrate with existing clinical workflows, electronic health records, and payer systems.
Amwell primarily generates revenue through platform subscriptions and visit-based services sold to healthcare providers and insurers. Its customer base includes large health systems, government programs, and commercial health plans. The company positions itself as an enterprise-focused alternative to direct-to-consumer telehealth providers, emphasizing scalability, interoperability, and long-term institutional relationships. Founded in 2006, Amwell evolved from an on-demand physician consultation service into a broader digital care enablement platform, culminating in its initial public offering in 2020.
Business Operations
Amwell operates through two primary business segments: Subscription and Platform Solutions and Visit Services. The Subscription and Platform Solutions segment includes recurring revenue from health systems and payers that license Amwell’s telehealth technology, including its Converge platform. The Visit Services segment includes per-visit clinical services delivered through Amwell’s affiliated provider network, including urgent care and specialty consults.
The company’s operations are primarily U.S.-based, with limited international activity tied to specific partnerships and acquired digital health assets. Amwell controls proprietary telehealth software, clinical workflow tools, and virtual care management capabilities. Key subsidiaries include Amwell Medical Group, which supports clinical service delivery, and SilverCloud Health, a digital behavioral health platform. The company also owns Conversa Health, a patient engagement and automated care interaction platform acquired to expand longitudinal and asynchronous care capabilities.
Strategic Position & Investments
Amwell’s strategic direction focuses on becoming a foundational digital care infrastructure provider for large healthcare organizations. Growth initiatives emphasize expanding enterprise platform adoption, increasing behavioral health offerings, and embedding telehealth into hybrid care delivery models. The company has invested significantly in platform development rather than consumer marketing, reflecting its long-term enterprise strategy.
Notable acquisitions include SilverCloud Health, which strengthened Amwell’s behavioral health portfolio, and Conversa Health, which expanded its capabilities in automated patient engagement and post-acute care management. Amwell has also maintained a strategic relationship with Google Cloud, supporting infrastructure scalability and artificial intelligence development. The company continues to invest in integrated care pathways, asynchronous communication, and data-driven clinical tools, though profitability remains a longer-term objective.
Geographic Footprint
Amwell is headquartered in Boston, Massachusetts, and its operations are concentrated in North America, particularly the United States. The company serves healthcare providers and insurers across most U.S. states through its virtual care platform and affiliated clinician network.
Internationally, Amwell has a more limited footprint, primarily through digital health assets and partnerships associated with United Kingdom and Ireland-based operations stemming from the SilverCloud Health business. While the company does not have a broad global clinical presence, its technology platform supports international scalability and selective cross-border deployments.
Leadership & Governance
Amwell was founded by brothers Ido Schoenberg and Roy Schoenberg, who continue to play central roles in the company’s leadership. The leadership team emphasizes a vision of technology-enabled, system-integrated healthcare that supports clinicians rather than disintermediating them. Corporate governance follows a dual-class share structure, with founders retaining significant voting control.
Key executives include:
- Ido Schoenberg – President and Chief Executive Officer
- Roy Schoenberg – Executive Vice President and President, Digital Services
- Robert Shepardson – Chief Financial Officer
- Mark Hirschhorn – Chief Operating Officer
- Dr. Allison Gardiner – Chief Medical Officer
The leadership team’s strategic philosophy prioritizes long-term platform adoption, clinical quality, and deep integration with health systems over short-term volume growth.
Verification Requirements
All information presented is derived from publicly available company disclosures, including SEC filings, investor communications, and coverage from established financial and healthcare industry publications. Where executive roles, international scope, or segment reporting may vary over time, descriptions reflect consensus across multiple reputable sources. Any discrepancies or updates not consistently confirmed across sources are considered data inconclusive based on available public information.